|
1
|
Else T, Kim AC, Sabolch A, Raymond VM,
Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ and Hammer
GD: Adrenocortical carcinoma. Endocr Rev. 35:282–326. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barlaskar FM and Hammer GD: The molecular
genetics of adrenocortical carcinoma. Rev Endocr Metab Disord.
8:343–348. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ragazzon B, Assié G and Bertherat J:
Transcriptome analysis of adrenocortical cancers: From molecular
classification to the identification of new treatments. Endocr
Relat Cancer. 18:R15–R27. 2011.PubMed/NCBI
|
|
4
|
Assié G, Letouzé E, Fassnacht M, Jouinot
A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K,
René-Corail F, et al: Integrated genomic characterization of
adrenocortical carcinoma. Nat Genet. 46:607–612. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Assié G, Jouinot A and Bertherat J: The
‘omics’ of adrenocortical tumours for personalized medicine. Nat
Rev Endocrinol. 10:215–228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fassnacht M, Libé R, Kroiss M and Allolio
B: Adrenocortical carcinoma: A clinician's update. Nat Rev
Endocrinol. 7:323–335. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fassnacht M, Kenn W and Allolio B: Adrenal
tumors: How to establish malignancy? J Endocrinol Invest.
27:387–399. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tauchmanovà L, Colao A, Marzano LA,
Sparano L, Camera L, Rossi A, Palmieri G, Marzano E, Salvatore M,
Pettinato G, et al: Andrenocortical carcinomas: Twelve-year
prospective experience. World J Surg. 28:896–903. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arlt W, Biehl M, Taylor AE, Hahner S, Libé
R, Hughes BA, Schneider P, Smith DJ, Stiekema H, Krone N, et al:
Urine steroid metabolomics as a biomarker tool for detecting
malignancy in adrenal tumors. J Clin Endocrinol Metab.
96:3775–3784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Terzolo M, Stigliano A, Chiodini I, Loli
P, Furlani L, Arnaldi G, Reimondo G, Pia A, Toscano V, Zini M, et
al: Italian Association of Clinical Endocrinologists: AME position
statement on adrenal incidentaloma. Eur J Endocrinol. 164:851–870.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Blake MA, Kalra MK, Sweeney AT, Lucey BC,
Maher MM, Sahani DV, Halpern EF, Mueller PR, Hahn PF and Boland GW:
Distinguishing benign from malignant adrenal masses: Multi-detector
row CT protocol with 10-minute delay. Radiology. 238:578–585. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Petersenn S, Richter PA, Broemel T, Ritter
CO, Deutschbein T, Beil FU, Allolio B and Fassnacht M: German ACC
Study Group: Computed tomography criteria for discrimination of
adrenal adenomas and adrenocortical carcinomas: Analysis of the
German ACC registry. Eur J Endocrinol. 172:415–422. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wong KK, Arabi M, Zerizer I, Al-Nahhas A,
Rubello D and Gross MD: Role of positron emission
tomography/computed tomography in adrenal and neuroendocrine
tumors: Fluorodeoxyglucose and nonfluorodeoxyglucose tracers. Nucl
Med Commun. 32:764–781. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hennings J, Lindhe O, Bergström M,
Långström B, Sundin A and Hellman P: [11C]metomidate positron
emission tomography of adrenocortical tumors in correlation with
histopathological findings. J Clin Endocrinol Metab. 91:1410–1414.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hahner S, Kreissl MC, Fassnacht M,
Haenscheid H, Bock S, Verburg FA, Knoedler P, Lang K, Reiners C,
Buck AK, et al: Functional characterization of adrenal lesions
using [123I]IMTO-SPECT/CT. J Clin Endocrinol Metab. 98:1508–1518.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Delellis RA, Lloyd RV and Heitz PU:
Pathology and Genetics of Tumours of Endocrine OrgansEble JN,
Sauter G, Epstein JE and Sesterhenn IA: IARC; Lyon: 2004
|
|
17
|
MacFarlane DA: Cancer of the adrenal
cortex; the natural history, prognosis and treatment in a study of
fifty-five cases. Ann R Coll Surg Engl. 23:155–186. 1958.PubMed/NCBI
|
|
18
|
Sullivan M, Boileau M and Hodges CV:
Adrenal cortical carcinoma. J Urol. 120:660–665. 1978.PubMed/NCBI
|
|
19
|
Fassnacht M, Johanssen S, Quinkler M,
Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH,
Hahner S and Allolio B: German Adrenocortical Carcinoma Registry
Group; European Network for the Study of Adrenal Tumors: Limited
prognostic value of the 2004 International Union Against Cancer
staging classification for adrenocortical carcinoma: Proposal for a
Revised TNM Classification. Cancer. 115:243–250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lughezzani G, Sun M, Perrotte P, Jeldres
C, Alasker A, Isbarn H, Budäus L, Shariat SF, Guazzoni G, Montorsi
F, et al: The European Network for the Study of Adrenal Tumors
staging system is prognostically superior to the international
union against cancer-staging system: A North American validation.
Eur J Cancer. 46:713–719. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Creemers SG, Hofland LJ, Korpershoek E,
Franssen GJ, van Kemenade FJ, de Herder WW and Feelders RA: Future
directions in the diagnosis and medical treatment of adrenocortical
carcinoma. Endocr Relat Cancer. 23:R43–R69. 2016.PubMed/NCBI
|
|
22
|
Stigliano A, Chiodini I, Giordano R,
Faggiano A, Canu L, Casa S Della, Loli P, Luconi M, Mantero F and
Terzolo M: Management of adrenocortical carcinoma: A consensus
statement of the Italian Society of Endocrinology (SIE). J
Endocrinol Invest. 39:103–121. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Crucitti F, Bellantone R, Ferrante A,
Boscherini M and Crucitti P: The ACC Italian Registry Study Group:
The Italian Registry for Adrenal Cortical Carcinoma: Analysis of a
multiinstitutional series of 129 patients. Surgery. 119:161–170.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Donatini G, Caiazzo R, Do Cao C, Aubert S,
Zerrweck C, El-Kathib Z, Gauthier T, Leteurtre E, Wemeau JL,
Vantyghem MC, et al: Long-term survival after adrenalectomy for
stage I/II adrenocortical carcinoma (ACC): A retrospective
comparative cohort study of laparoscopic versus open approach. Ann
Surg Oncol. 21:284–291. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vaughan ED Jr.: Diseases of the adrenal
gland. Med Clin North Am. 88:443–466. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang H and Fojo T: Adjuvant mitotane for
adrenocortical cancer - a recurring controversy. J Clin Endocrinol
Metab. 93:3730–3732. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Icard P, Goudet P, Charpenay C,
Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF and
Proye C: Adrenocortical carcinomas: Surgical trends and results of
a 253-patient series from the French Association of Endocrine
Surgeons study group. World J Surg. 25:891–897. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lombardi CP, Raffaelli M, De Crea C,
Boniardi M, De Toma G, Marzano LA, Miccoli P, Minni F, Morino M,
Pelizzo MR, et al: Open versus endoscopic adrenalectomy in the
treatment of localized (stage I/II) adrenocortical carcinoma:
Results of a multiinstitutional Italian survey. Surgery.
152:1158–1164. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Porpiglia F, Fiori C, Daffara F, Zaggia B,
Bollito E, Volante M, Berruti A and Terzolo M: Retrospective
evaluation of the outcome of open versus laparoscopic adrenalectomy
for stage I and II adrenocortical cancer. Eur Urol. 57:873–878.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reibetanz J, Jurowich C, Erdogan I, Nies
C, Rayes N, Dralle H, Behrend M, Allolio B and Fassnacht M: German
ACC study group: Impact of lymphadenectomy on the oncologic outcome
of patients with adrenocortical carcinoma. Ann Surg. 255:363–369.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gaujoux S and Brennan MF: Recommendation
for standardized surgical management of primary adrenocortical
carcinoma. Surgery. 152:123–132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kemp CD, Ripley RT, Mathur A, Steinberg
SM, Nguyen DM, Fojo T and Schrump DS: Pulmonary resection for
metastatic adrenocortical carcinoma: The National Cancer Institute
experience. Ann Thorac Surg. 92:1195–1200. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ripley RT, Kemp CD, Davis JL, Langan RC,
Royal RE, Libutti SK, Steinberg SM, Wood BJ, Kammula US, Fojo T, et
al: Liver resection and ablation for metastatic adrenocortical
carcinoma. Ann Surg Oncol. 18:1972–1979. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stojadinovic A, Ghossein RA, Hoos A,
Nissan A, Marshall D, Dudas M, Cordon-Cardo C, Jaques DP and
Brennan MF: Adrenocortical carcinoma: Clinical, morphologic, and
molecular characterization. J Clin Oncol. 20:941–950. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Datrice NM, Langan RC, Ripley RT, Kemp CD,
Steinberg SM, Wood BJ, Libutti SK, Fojo T, Schrump DS and Avital I:
Operative management for recurrent and metastatic adrenocortical
carcinoma. J Surg Oncol. 105:709–713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Erdogan I, Deutschbein T, Jurowich C,
Kroiss M, Ronchi C, Quinkler M, Waldmann J, Willenberg HS,
Beuschlein F, Fottner C, et al: German Adrenocortical Carcinoma
Study Group: The role of surgery in the management of recurrent
adrenocortical carcinoma. J Clin Endocrinol Metab. 98:181–191.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schteingart DE, Doherty GM, Gauger PG,
Giordano TJ, Hammer GD, Korobkin M and Worden FP: Management of
patients with adrenal cancer: Recommendations of an international
consensus conference. Endocr Relat Cancer. 12:667–680. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin CW, Chang YH and Pu HF: Mitotane
exhibits dual effects on steroidogenic enzymes gene transcription
under basal and cAMP-stimulating microenvironments in NCI-H295
cells. Toxicology. 298:14–23. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lehmann TP, Wrzesiński T and Jagodziński
PP: The effect of mitotane on viability, steroidogenesis and gene
expression in NCI-H295R adrenocortical cells. Mol Med Rep.
7:893–900. 2013.PubMed/NCBI
|
|
40
|
van Slooten H, Moolenaar AJ, van Seters AP
and Smeenk D: The treatment of adrenocortical carcinoma with
o,p'-DDD: Prognostic implications of serum level monitoring. Eur J
Cancer Clin Oncol. 20:47–53. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hermsen IG, Fassnacht M, Terzolo M,
Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A,
Chadarevian R, Schlumberger M, et al: Plasma concentrations of
o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to
mitotane in adrenocortical carcinoma: Results of a retrospective
ENS@T multicenter study. J Clin Endocrinol Metab. 96:1844–1851.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kerkhofs TM, Baudin E, Terzolo M, Allolio
B, Chadarevian R, Mueller HH, Skogseid B, Leboulleux S, Mantero F,
Haak HR, et al: Comparison of two mitotane starting dose regimens
in patients with advanced adrenocortical carcinoma. J Clin
Endocrinol Metab. 98:4759–4767. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fassnacht M and Allolio B: Clinical
management of adrenocortical carcinoma. Best Pract Res Clin
Endocrinol Metab. 23:273–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Terzolo M, Baudin AE, Ardito A, Kroiss M,
Leboulleux S, Daffara F, Perotti P, Feelders RA, deVries JH, Zaggia
B, et al: Mitotane levels predict the outcome of patients with
adrenocortical carcinoma treated adjuvantly following radical
resection. Eur J Endocrinol. 169:263–270. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mauclère-Denost S, Leboulleux S, Borget I,
Paci A, Young J, Al Ghuzlan A, Deandreis D, Drouard L, Tabarin A,
Chanson P, et al: High-dose mitotane strategy in adrenocortical
carcinoma: Prospective analysis of plasma mitotane measurement
during the first 3 months of follow-up. Eur J Endocrinol.
166:261–268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
van Erp NP, Guchelaar HJ, Ploeger BA,
Romijn JA, Hartigh J and Gelderblom H: Mitotane has a strong and a
durable inducing effect on CYP3A4 activity. Eur J Endocrinol.
164:621–626. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kroiss M, Quinkler M, Lutz WK, Allolio B
and Fassnacht M: Drug interactions with mitotane by induction of
CYP3A4 metabolism in the clinical management of adrenocortical
carcinoma. Clin Endocrinol (Oxf). 75:585–591. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Haak HR, Hermans J, van De Velde CJ,
Lentjes EG, Goslings BM, Fleuren GJ and Krans HM: Optimal treatment
of adrenocortical carcinoma with mitotane: Results in a consecutive
series of 96 patients. Br J Cancer. 69:947–951. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Baudin E, Pellegriti G, Bonnay M,
Penfornis A, Laplanche A, Vassal G and Schlumberger M: Impact of
monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD)
levels on the treatment of patients with adrenocortical carcinoma.
Cancer. 92:1385–1392. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Terzolo M, Angeli A, Fassnacht M, Daffara
F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P,
Grossrubatscher E, et al: Adjuvant mitotane treatment for
adrenocortical carcinoma. N Engl J Med. 356:2372–2380. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Berruti A, Baudin E, Gelderblom H, Haak
HR, Porpiglia F, Fassnacht M and Pentheroudakis G: ESMO Guidelines
Working Group: Adrenal cancer: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 23 Suppl
7:vii131–vii138. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bates SE, Shieh CY, Mickley LA, Dichek HL,
Gazdar A, Loriaux DL and Fojo AT: Mitotane enhances cytotoxicity of
chemotherapy in cell lines expressing a multidrug resistance gene
(mdr-1/P-glycoprotein) which is also expressed by adrenocortical
carcinomas. J Clin Endocrinol Metab. 73:18–29. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Berruti A, Terzolo M, Sperone P, Pia A,
Casa S Della, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero
F, et al: Etoposide, doxorubicin and cisplatin plus mitotane in the
treatment of advanced adrenocortical carcinoma: A large prospective
phase II trial. Endocr Relat Cancer. 12:657–666. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Khan TS, Imam H, Juhlin C, Skogseid B,
Gröndal S, Tibblin S, Wilander E, Oberg K and Eriksson B:
Streptozocin and o,p'DDD in the treatment of adrenocortical cancer
patients: Long-term survival in its adjuvant use. Ann Oncol.
11:1281–1287. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bukowski RM, Wolfe M, Levine HS, Crawford
DE, Stephens RL, Gaynor E and Harker WG: Phase II trial of mitotane
and cisplatin in patients with adrenal carcinoma: A Southwest
Oncology Group study. J Clin Oncol. 11:161–165. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Schteingart DE: Conventional and novel
strategies in the treatment of adrenocortical cancer. Braz J Med
Biol Res. 33:1197–1200. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bonacci R, Gigliotti A, Baudin E,
Wion-Barbot N, Emy P, Bonnay M, Cailleux AF, Nakib I and
Schlumberger M: Réseau Comète: Cytotoxic therapy with etoposide and
cisplatin in advanced adrenocortical carcinoma. Br J Cancer.
78:546–549. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Burgess MA, Legha SS and Sellin RV:
Chemotherapy with cisplatinum and etoposide (UP16) for patients
with advanced adrenal cortical carcinoma (ACC). Proc ASCO.
12:1881993.
|
|
59
|
Williamson SK, Lew D, Miller GJ, Balcerzak
SP, Baker LH and Crawford ED: Phase II evaluation of cisplatin and
etoposide followed by mitotane at disease progression in patients
with locally advanced or metastatic adrenocortical carcinoma: A
Southwest Oncology Group Study. Cancer. 88:1159–1165. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Fassnacht M, Terzolo M, Allolio B, Baudin
E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A,
Jarzab B, et al: FIRM-ACT Study Group: Combination chemotherapy in
advanced adrenocortical carcinoma. N Engl J Med. 366:2189–2197.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Germano A, Rapa I, Volante M, Lo Buono N,
Carturan S, Berruti A, Terzolo M and Papotti M: Cytotoxic activity
of gemcitabine, alone or in combination with mitotane, in
adrenocortical carcinoma cell lines. Mol Cell Endocrinol. 382:1–7.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Fassnacht M, Hahner S, Polat B, Koschker
AC, Kenn W, Flentje M and Allolio B: Efficacy of adjuvant
radiotherapy of the tumor bed on local recurrence of adrenocortical
carcinoma. J Clin Endocrinol Metab. 91:4501–4504. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sabolch A, Feng M, Griffith K, Hammer G,
Doherty G and Ben-Josef E: Adjuvant and definitive radiotherapy for
adrenocortical carcinoma. Int J Radiat Oncol Biol Phys.
80:1477–1484. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Habra MA, Ejaz S, Feng L, Das P, Deniz F,
Grubbs EG, Phan A, Waguespack SG, Ayala-Ramirez M, Jimenez C, et
al: A retrospective cohort analysis of the efficacy of adjuvant
radiotherapy after primary surgical resection in patients with
adrenocortical carcinoma. J Clin Endocrinol Metab. 98:192–197.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cerquetti L, Bucci B, Marchese R, Misiti
S, De Paula U, Miceli R, Muleti A, Amendola D, Piergrossi P,
Brunetti E, et al: Mitotane increases the radiotherapy inhibitory
effect and induces G2-arrest in combined treatment on both H295R
and SW13 adrenocortical cell lines. Endocr Relat Cancer.
15:623–634. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Cerquetti L, Sampaoli C, Amendola D, Bucci
B, Misiti S, Raza G, De Paula U, Marchese R, Brunetti E, Toscano V,
et al: Mitotane sensitizes adrenocortical cancer cells to ionizing
radiations by involvement of the cyclin B1/CDK complex in G2 arrest
and mismatch repair enzymes modulation. Int J Oncol. 37:493–501.
2010.PubMed/NCBI
|
|
67
|
Polat B, Fassnacht M, Pfreundner L,
Guckenberger M, Bratengeier K, Johanssen S, Kenn W, Hahner S,
Allolio B and Flentje M: Radiotherapy in adrenocortical carcinoma.
Cancer. 115:2816–2823. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
De Reyniès A, Assié G, Rickman DS, Tissier
F, Groussin L, René-Corail F, Dousset B, Bertagna X, Clauser E and
Bertherat J: Gene expression profiling reveals a new classification
of adrenocortical tumors and identifies molecular predictors of
malignancy and survival. J Clin Oncol. 27:1108–1115. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Barlaskar FM, Spalding AC, Heaton JH,
Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E and Hammer GD:
Preclinical targeting of the type I insulin-like growth factor
receptor in adrenocortical carcinoma. J Clin Endocrinol Metab.
94:204–212. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Tacon LJ, Prichard RS, Soon PSH, Robinson
BG, Clifton-Bligh RJ and Sidhu SB: Current and emerging therapies
for advanced adrenocortical carcinoma. Oncologist. 16:36–48. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Haluska P, Worden F, Olmos D, Yin D,
Schteingart D, Batzel GN, Paccagnella ML, De Bono JS, Gualberto A
and Hammer GD: Safety, tolerability, and pharmacokinetics of the
anti-IGF-1R monoclonal antibody figitumumab in patients with
refractory adrenocortical carcinoma. Cancer Chemother Pharmacol.
65:765–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Carden CP, Frentzas S and Langham M:
Preliminary activity in adrenocortical tumor (ACC) in phase I dose
escalation study of intermittent oral dosing of OSI-906, a
small-molecule insulin-like growth factor-1 receptor (IGF-1R)
tyrosine kinase inhibitor in patients with advanced solid tumors. J
Clin Oncol. 27:35442009.
|
|
73
|
Fassnacht M, Berruti A, Baudin E, Demeure
MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL,
et al: Linsitinib (OSI-906) versus placebo for patients with
locally advanced or metastatic adrenocortical carcinoma: A
double-blind, randomised, phase 3 study. Lancet Oncol. 16:426–435.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Doghman M, El Wakil A, Cardinaudet B,
Thomas E, Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC,
Zambetti GP and Lalli E: Regulation of IGF-mTOR signalling by miRNA
in childhood adrenocortical tumors. Cancer Res. 70:4666–4675. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
De Martino MC, van Koetsveld PM, Pivonello
R and Hofland LJ: Role of the mTOR pathway in normal and tumoral
adrenal cells. Neuroendocrinology. 92 Suppl 1:28–34. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Naing A, Kurzrock R, Burger A, Gupta S,
Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, et al:
Phase I trial of cixutumumab combined with temsirolimus in patients
with advanced cancer. Clin Cancer Res. 17:6052–6060. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Lerario AM, Worden FP, Ramm CA, Hesseltine
EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K and Hammer GD: The
combination of insulin-like growth factor receptor 1 (IGF1R)
antibody cixutumumab and mitotane as a first-line therapy for
patients with recurrent/metastatic adrenocortical carcinoma: A
multi-institutional NCI-sponsored trial. Horm Cancer. 5:232–239.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wortmann S, Quinkler M, Ritter C, Kroiss
M, Johanssen S, Hahner S, Allolio B and Fassnacht M: Bevacizumab
plus capecitabine as a salvage therapy in advanced adrenocortical
carcinoma. Eur J Endocrinol. 162:349–356. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Chacón R, Tossen G, Loria FS and Chacón M:
CASE 2. Response in a patient with metastatic adrenal cortical
carcinoma with thalidomide. J Clin Oncol. 23:1579–1580. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Kroiss M, Quinkler M, Johanssen S, van Erp
NP, Lankheet N, Pöllinger A, Laubner K, Strasburger CJ, Hahner S,
Müller HH, et al: Sunitinib in refractory adrenocortical carcinoma:
A phase II, single-arm, open-label trial. J Clin Endocrinol Metab.
97:3495–3503. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Hong DS, Sebti SM, Newman RA, Blaskovich
MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, et
al: Phase I trial of a combination of the multikinase inhibitor
sorafenib and the farnesyltransferase inhibitor tipifarnib in
advanced malignancies. Clin Cancer Res. 15:7061–7068. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Butler C, Butler WM and Rizvi AA:
Sustained remission with the kinase inhibitor sorafenib in stage IV
metastatic adrenocortical carcinoma. Endocr Pract. 16:441–445.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Berruti A, Sperone P, Ferrero A, Germano
A, Ardito A, Priola AM, De Francia S, Volante M, Daffara F,
Generali D, et al: Phase II study of weekly paclitaxel and
sorafenib as second/third-line therapy in patients with
adrenocortical carcinoma. Eur J Endocrinol. 166:451–458. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Lee JO, Lee KW, Kim CJ, Kim YJ, Lee HE,
Kim H, Kim JH, Bang SM, Kim JS and Lee JS: Metastatic
adrenocortical carcinoma treated with sunitinib: A case report. Jpn
J Clin Oncol. 39:183–185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Gangadhar TC, Cohen EEW, Wu K, Janisch L,
Geary D, Kocherginsky M, House LK, Ramirez J, Undevia SD, Maitland
ML, et al: Two drug interaction studies of sirolimus in combination
with sorafenib or sunitinib in patients with advanced malignancies.
Clin Cancer Res. 17:1956–1963. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Xu YZ, Zhu Y, Shen ZJ, Sheng JY, He HC, Ma
G, Qi YC, Zhao JP, Wu YX, Rui WB, et al: Significance of
heparanase-1 and vascular endothelial growth factor in
adrenocortical carcinoma angiogenesis: Potential for therapy.
Endocrine. 40:445–451. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Assié G, Guillaud-Bataille M, Ragazzon B,
Bertagna X, Bertherat J and Clauser E: The pathophysiology,
diagnosis and prognosis of adrenocortical tumors revisited by
transcriptome analyses. Trends Endocrinol Metab. 21:325–334. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Quinkler M, Hahner S, Wortmann S,
Johanssen S, Adam P, Ritter C, Strasburger C, Allolio B and
Fassnacht M: Treatment of advanced adrenocortical carcinoma with
erlotinib plus gemcitabine. J Clin Endocrinol Metab. 93:2057–2062.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Samnotra V, Vassilopoulou-Sellin R and
Fojo AT: A phase II trial of gefitinib monotherapy in patients with
unresectable adrenocortical carcinoma (ACC). J Clin Oncol.
27:155272007.
|
|
90
|
Gross DJ, Munter G, Bitan M, Siegal T,
Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A,
et al: Israel Glivec in Solid Tumors Study Group: The role of
imatinib mesylate (Glivec) for treatment of patients with malignant
endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer.
13:535–540. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Adam P, Hahner S, Hartmann M, Heinrich B,
Quinkler M, Willenberg HS, Saeger W, Sbiera S, Schmull S, Voelker
HU, et al: Epidermal growth factor receptor in adrenocortical
tumors: Analysis of gene sequence, protein expression and
correlation with clinical outcome. Mod Pathol. 23:1596–1604. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Gagliano T, Gentilin E, Benfini K, Di
Pasquale C, Tassinari M, Falletta S, Feo C, Tagliati F, Uberti ED
and Zatelli MC: Mitotane enhances doxorubicin cytotoxic activity by
inhibiting P-gp in human adrenocortical carcinoma cells. Endocrine.
47:943–951. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Abraham J, Bakke S, Rutt A, Meadows B,
Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R, et
al: A phase II trial of combination chemotherapy and surgical
resection for the treatment of metastatic adrenocortical carcinoma:
Continuous infusion doxorubicin, vincristine, and etoposide with
daily mitotane as a P-glycoprotein antagonist. Cancer.
94:2333–2343. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kahn CR, Chen L and Cohen SE: Unraveling
the mechanism of action of thiazolidinediones. J Clin Invest.
106:1305–1307. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Betz MJ, Shapiro I, Fassnacht M, Hahner S,
Reincke M and Beuschlein F: German and Austrian Adrenal Network:
Peroxisome proliferator-activated receptor-γ agonists suppress
adrenocortical tumor cell proliferation and induce differentiation.
J Clin Endocrinol Metab. 90:3886–3896. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Ferruzzi P, Ceni E, Tarocchi M, Grappone
C, Milani S, Galli A, Fiorelli G, Serio M and Mannelli M:
Thiazolidinediones inhibit growth and invasiveness of the human
adrenocortical cancer cell line H295R. J Clin Endocrinol Metab.
90:1332–1339. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Luconi M, Mangoni M, Gelmini S, Poli G,
Nesi G, Francalanci M, Pratesi N, Cantini G, Lombardi A, Pepi M, et
al: Rosiglitazone impairs proliferation of human adrenocortical
cancer: Preclinical study in a xenograft mouse model. Endocr Relat
Cancer. 17:169–177. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Cerquetti L, Sampaoli C, Amendola D, Bucci
B, Masuelli L, Marchese R, Misiti S, De Venanzi A, Poggi M, Toscano
V, et al: Rosiglitazone induces autophagy in H295R and cell cycle
deregulation in SW13 adrenocortical cancer cells. Exp Cell Res.
317:1397–1410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Tissier F, Cavard C, Groussin L,
Perlemoine K, Fumey G, Hagneré AM, René-Corail F, Jullian E,
Gicquel C, Bertagna X, et al: Mutations of β-catenin in
adrenocortical tumors: Activation of the Wnt signaling pathway is a
frequent event in both benign and malignant adrenocortical tumors.
Cancer Res. 65:7622–7627. 2005.PubMed/NCBI
|
|
100
|
Gaujoux S, Grabar S, Fassnacht M, Ragazzon
B, Launay P, Libé R, Chokri I, Audebourg A, Royer B, Sbiera S, et
al: β-catenin activation is associated with specific clinical and
pathologic characteristics and a poor outcome in adrenocortical
carcinoma. Clin Cancer Res. 17:328–336. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Doghman M, Cazareth J and Lalli E: The T
cell factor/β-catenin antagonist PKF115-584 inhibits proliferation
of adrenocortical carcinoma cells. J Clin Endocrinol Metab.
93:3222–3225. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Gaujoux S, Hantel C, Launay P, Bonnet S,
Perlemoine K, Lefèvre L, Guillaud-Bataille M, Beuschlein F, Tissier
F, Bertherat J, et al: Silencing mutated β-catenin inhibits cell
proliferation and stimulates apoptosis in the adrenocortical cancer
cell line H295R. PLoS One. 8:e557432013. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Demeure MJ, Bussey KJ and Kirschner LS:
Targeted therapies for adrenocortical carcinoma: IGF and beyond.
Horm Cancer. 2:385–392. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Sbiera S, Schmull S, Assie G, Voelker HU,
Kraus L, Beyer M, Ragazzon B, Beuschlein F, Willenberg HS, Hahner
S, et al: High diagnostic and prognostic value of steroidogenic
factor-1 expression in adrenal tumors. J Clin Endocrinol Metab.
95:E161–E171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Duregon E, Volante M, Giorcelli J, Terzolo
M, Lalli E and Papotti M: Diagnostic and prognostic role of
steroidogenic factor 1 in adrenocortical carcinoma: A validation
study focusing on clinical and pathologic correlates. Hum Pathol.
44:822–828. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Doghman M, Karpova T, Rodrigues GA,
Arhatte M, De Moura J, Cavalli LR, Virolle V, Barbry P, Zambetti
GP, Figueiredo BC, et al: Increased steroidogenic factor-1 dosage
triggers adrenocortical cell proliferation and cancer. Mol
Endocrinol. 21:2968–2987. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Ehrlund A, Jonsson P, Vedin LL, Williams
C, Gustafsson JÅ and Treuter E: Knockdown of SF-1 and RNF31 affects
components of steroidogenesis, TGFβ, and Wnt/β-catenin signaling in
adrenocortical carcinoma cells. PLoS One. 7:e320802012. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Doghman M, Cazareth J, Douguet D, Madoux
F, Hodder P and Lalli E: Inhibition of adrenocortical carcinoma
cell proliferation by steroidogenic factor-1 inverse agonists. J
Clin Endocrinol Metab. 94:2178–2183. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Chuman Y, Zhan Z and Fojo T: Construction
of gene therapy vectors targeting adrenocortical cells: Enhancement
of activity and specificity with agents modulating the cyclic
adenosine 3′,5′-monophosphate pathway. J Clin Endocrinol Metab.
85:253–262. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Sbiera S, Wortmann S and Fassnacht M:
Dendritic cell based immunotherapy - a promising therapeutic
approach for endocrine malignancies. Horm Metab Res. 40:89–98.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Papewalis C, Fassnacht M, Willenberg HS,
Domberg J, Fenk R, Rohr UP, Schinner S, Bornstein SR, Scherbaum WA
and Schott M: Dendritic cells as potential adjuvant for
immunotherapy in adrenocortical carcinoma. Clin Endocrinol (Oxf).
65:215–222. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
van Koetsveld PM, Vitale G, Feelders RA,
Waaijers M, Sprij-Mooij DM, De Krijger RR, Speel EJ, Hofland J,
Lamberts SW, De Herder WW, et al: Interferon-β is a potent
inhibitor of cell growth and cortisol production in vitro and
sensitizes human adrenocortical carcinoma cells to mitotane. Endocr
Relat Cancer. 20:443–454. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Liu-Chittenden Y, Jain M, Kumar P, Patel
D, Aufforth R, Neychev V, Sadowski S, Gara SK, Joshi BH,
Cottle-Delisle C, et al: Phase I trial of systemic intravenous
infusion of interleukin-13-Pseudomonas exotoxin in patients with
metastatic adrenocortical carcinoma. Cancer Med. 4:1060–1068. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Soon PS, Tacon LJ, Gill AJ, Bambach CP,
Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson
BG, et al: miR-195 and miR-483-5p identified as predictors of poor
prognosis in adrenocortical cancer. Clin Cancer Res. 15:7684–7692.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Glover AR, Zhao JT, Gill AJ, Weiss J,
Mugridge N, Kim E, Feeney AL, Ip JC, Reid G, Clarke S, et al:
MicroRNA-7 as a tumor suppressor and novel therapeutic for
adrenocortical carcinoma. Oncotarget. 6:36675–36688.
2015.PubMed/NCBI
|
|
117
|
De Cremoux P, Rosenberg D, Goussard J,
Brémont-Weil C, Tissier F, Tran-Perennou C, Groussin L, Bertagna X,
Bertherat J and Raffin-Sanson ML: Expression of progesterone and
estradiol receptors in normal adrenal cortex, adrenocortical
tumors, and primary pigmented nodular adrenocortical disease.
Endocr Relat Cancer. 15:465–474. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Barzon L, Masi G, Pacenti M, Trevisan M,
Fallo F, Remo A, Martignoni G, Montanaro D, Pezzi V and Palù G:
Expression of aromatase and estrogen receptors in human
adrenocortical tumors. Virchows Arch. 452:181–191. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Montanaro D, Maggiolini M, Recchia AG,
Sirianni R, Aquila S, Barzon L, Fallo F, Andò S and Pezzi V:
Antiestrogens upregulate estrogen receptor β expression and inhibit
adrenocortical H295R cell proliferation. J Mol Endocrinol.
35:245–256. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Sirianni R, Zolea F, Chimento A, Ruggiero
C, Cerquetti L, Fallo F, Pilon C, Arnaldi G, Carpinelli G,
Stigliano A, et al: Targeting estrogen receptor-α reduces
adrenocortical cancer (ACC) cell growth in vitro and in vivo:
Potential therapeutic role of Selective Estrogen Receptor
modulators (SERMs) for ACC treatment. J Clin End Metab.
97:E2238–E2250. 2012. View Article : Google Scholar
|
|
121
|
Chimento A, Sirianni R, Casaburi I, Zolea
F, Rizza P, Avena P, Malivindi R, De Luca A, Campana C, Martire E,
et al: GPER agonist G-1 decreases adrenocortical carcinoma (ACC)
cell growth in vitro and in vivo. Oncotarget. 6:19190–19203. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Giguère V, Yang N, Segui P and Evans RM:
Identification of a new class of steroid hormone receptors. Nature.
331:91–94. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Deblois G and Giguère V: Functional and
physiological genomics of estrogen-related receptors (ERRs) in
health and disease. Biochim Biophys Acta. 1812:1032–1040. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Casaburi I, Avena P, De Luca A, Chimento
A, Sirianni R, Malivindi R, Rago V, Fiorillo M, Domanico F, Campana
C, et al: Estrogen related receptor α (ERRα) a promising target for
the therapy of adrenocortical carcinoma (ACC). Oncotarget.
6:25135–25148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Hahner S, Kreissl MC, Fassnacht M,
Haenscheid H, Knoedler P, Lang K, Buck AK, Reiners C, Allolio B and
Schirbel A: [131I]iodometomidate for targeted radionuclide therapy
of advanced adrenocortical carcinoma. J Clin Endocrinol Metab.
97:914–922. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Wood BJ, Abraham J, Hvizda JL, Alexander
HR and Fojo T: Radiofrequency ablation of adrenal tumors and
adrenocortical carcinoma metastases. Cancer. 97:554–560. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Cazejust J, De B, aère T, Auperin A,
Deschamps F, Hechelhammer L, Abdel-Rehim M, Schlumberger M,
Leboulleux S and Baudin E: Transcatheter arterial chemoembolization
for liver metastases in patients with adrenocortical carcinoma. J
Vasc Interv Radiol. 21:1527–1532. 2010. View Article : Google Scholar : PubMed/NCBI
|
